Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
boxed-textEmery P et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized,
double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390–1400
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Rheumatology Fellow in and MH Weisman is the Director of the Division of Rheumatology, Cedars–Sinai Medical Center, Los Angeles, CA, USA
Dr Michael H Weisman is involved in research support for Amgen, Abbott, Bristol Myers Squibb (BMS), Centocor, Genentech, Human Genome Sciences (HGS), PDL. Dr Weisman is also involved as a
Consultant and on the Advisory Boar for Abbott, Bristol Myers Squibb (BMS), Coley Pharmaceutical, ELAN, Human Genome Sciences (HGS), Rigel, Roche, Vertex Pharmaceutical, and UCB Pharma.
Anyone you share the following link with will be able to read this content: